文献速递浆细胞疾病

多发性骨髓瘤免疫状态与免疫治疗患者选择:一项提议

Immune status and selection of patients for immunotherapy in myeloma: a proposal.
PubMed 文献 · Blood Adv · 2024-01-01

本文讨论多发性骨髓瘤(MM)中免疫状态与免疫治疗后结局的现有数据及其局限性,提出MM存在5种空间免疫类型:免疫耗竭型、免疫允许型、免疫排斥型、免疫抑制型和免疫抵抗型,作为优化特定免疫治疗应用及患者选择的初步框架。

要点

  • MM中系统性和区域性免疫的预先变异正成为当前免疫治疗及疫苗疗效的主要决定因素。
  • MM是多灶性恶性肿瘤,整合肿瘤空间特征和免疫靶点与免疫细胞生物学可能对优化免疫治疗至关重要。
  • 作者提出5种空间免疫类型:免疫耗竭型、免疫允许型、免疫排斥型、免疫抑制型和免疫抵抗型。

核心结论

  • 预先存在的系统性和/或区域性免疫变异正成为当前免疫治疗及疫苗疗效的主要决定因素。
  • 整合肿瘤空间特征及免疫靶点与免疫细胞生物学可能对优化MM免疫治疗(包括T细胞重定向)至关重要。
  • 作者提出5种空间免疫类型可能为MM特定免疫治疗的最佳应用提供初步框架,并可能有助于优化新兴免疫治疗的患者选择以改善结局。

研究设计与样本

  • 本文为针对MM免疫状态与免疫治疗后结局现有数据的讨论与提议,非系统检索。

主要发现

  • 基于招募和重定向内源性和/或合成免疫的新兴免疫方法如嵌合抗原受体T细胞或双特异性抗体正在改变MM的临床管理。
  • 免疫系统对骨髓瘤治疗抗肿瘤效应的贡献日益受到重视。
  • MM的临床恶性起源于骨髓瘤发生早期开始的系统性免疫改变以及受空间结构影响的区域免疫变化。
  • 免疫细胞的预先存在和治疗诱导的变化与MM患者结局相关,包括免疫治疗后。
  • MM是多灶性恶性肿瘤,与实体瘤一样,整合肿瘤空间方面和考虑免疫靶点与免疫细胞生物学可能至关重要。

关键数值与推荐

  • 作者提出5种不同的MM空间免疫类型:免疫耗竭型、免疫允许型、免疫排斥型、免疫抑制型和免疫抵抗型。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Newer immune-based approaches based on recruitment and redirection of endogenous and/or synthetic immunity such as chimeric antigen receptor T cells or bispecific antibodies are transforming the clinical management of multiple myeloma (MM). Contributions of the immune system to the antitumor effects of myeloma therapies are also increasingly appreciated. Clinical malignancy in MM originates in the setting of systemic immune alterations that begin early in myelomagenesis and regional changes in immunity affected by spatial contexture. Preexisting and therapy-induced changes in immune cells correlate with outcomes in patients with MM including after immune therapies. Here, we discuss insights from and limitations of available data about immune status and outcomes after immune therapies in patients with MM. Preexisting variation in systemic and/or regional immunity is emerging as a major determinant of the efficacy of current immune therapies as well as vaccines. However, MM is a multifocal malignancy. As with solid tumors, integrating spatial aspects of the tumor and consideration of immune targets with the biology of immune cells may be critical to optimizing the application of immune therapy, including T-cell redirection, in MM. We propose 5 distinct spatial immune types of MM that may provide an initial framework for the optimal application of specific immune therapies in MM: immune depleted, immune permissive, immune excluded, immune suppressed, and immune resistant. Such considerations may also help optimize rational patient selection for emerging immune therapies to improve outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dhodapkar MV. Immune status and selection of patients for immunotherapy in myeloma: a proposal. Blood Adv. 2024. PMID: 38564776. doi:10.1182/bloodadvances.2023011242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。